Myriad’s MyRisk ® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR ® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a ...

Jessica Ko saw others sharing their DNA results online and decided to take a test. The results have changed how she sees ...

Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform.

MyRisk. With the development of RiskScore, Myriad Genetics has developed the only genetic test that combines the assessment for hereditary cancer risk with the genomic breast cancer risk ...

Myriad Genetics, Inc. MYGN recently made SneakPeek available over the counter in more than 8,800 retail locations nationwide.

Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

MyRisk is the first hereditary cancer ... President and Chief Clinical Officer of Oncology, Myriad Genetics. “By making germline testing interoperable with OncoEMR, we aim to simplify the ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform. This ...